Mutation News and Research

RSS

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and  Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.

2 Jun 2014

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according to a multicenter interim study published in the OnLine First edition of the New England Journal of Medicine.

2 Jun 2014

Study suggests new targets for treating rare genetic disorder and cancer

The combined action of two enzymes, Srs2 and Exo1, prevents and repairs common genetic mutations in growing yeast cells, according to a new study led by scientists at NYU Langone Medical Center.

2 Jun 2014

Patients with advanced colorectal cancer respond well to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.

2 Jun 2014

Collaborative research effort produces new genetic insights into brainstem glioma

A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.

2 Jun 2014

BRCA2 gene doubles lung cancer risk among smokers

Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals.

2 Jun 2014

Scientists define genetic cause for two types of birth defects in newborn boys

Baylor College of Medicine scientists defined a previously unrecognized genetic cause for two types of birth defects found in newborn boys, described in a report published today in the journal Nature Medicine.

2 Jun 2014

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Myriad Genetics, Inc. today presented several clinical studies on the Myriad myRisk- Hereditary Cancer test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

2 Jun 2014

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

From Quest Diagnostics 2 Jun 2014

Particular genetic variation in humans linked with blond hair

A single-letter change in the genetic code is enough to generate blond hair in humans, in dramatic contrast to our dark-haired ancestors.

2 Jun 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

31 May 2014

New software tool helps identify genetic mutations linked to increased risk for cancer

Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer.

31 May 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

31 May 2014

NCI awards 'provocative questions' grants to Jackson lab researchers

Jackson Laboratory Assistant Professors Jennifer Trowbridge, Ph.D., and Chengkai Dai, M.D., Ph.D., have each received new federal research grants through a funding mechanism designed to address "provocative questions" about cancer set out by the National Cancer Institute (NCI).

31 May 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

Mutation News and Research

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Molecular mechanism linked to increased risk of diabetes in people with cystic fibrosis

Ibrutinib outperforms ofatumumab as second-line therapy for CLL treatment

Study suggests new targets for treating rare genetic disorder and cancer

Patients with advanced colorectal cancer respond well to new combination therapy

Collaborative research effort produces new genetic insights into brainstem glioma

BRCA2 gene doubles lung cancer risk among smokers

Scientists define genetic cause for two types of birth defects in newborn boys

Myriad myRisk test solves overlap dilemma between hereditary cancer syndromes

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Particular genetic variation in humans linked with blond hair

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Amgen presents extended analysis of PEAK study data at ASCO

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New software tool helps identify genetic mutations linked to increased risk for cancer

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

NCI awards 'provocative questions' grants to Jackson lab researchers

ArQule to present tivantinib clinical trial data at ASCO 2014

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News